Lv3
380 积分 2024-08-08 加入
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
8天前
已完结
ZT-01: A novel somatostatin receptor 2 antagonist for restoring the glucagon response to hypoglycaemia in type 1 diabetes
9天前
已完结
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3 A Somatostatin Receptor Antagonist
9天前
已完结
Chapter 21 - Regulatory toxicology testing for pharmaceuticals
15天前
已关闭
In-vivo two-photon visualization and quantitative detection of redox state of cancer
17天前
已完结
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
25天前
已完结
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer
25天前
已完结
Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants
25天前
已完结
Opportunities and limitations of B cell depletion approaches in SLE
25天前
已完结
Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus
25天前
已完结
皖公网安备34019202002308
